September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The impact of visual field progression on performance-based measures, vision-related quality of life, and clinical findings in patients with glaucoma: 2-year results
Author Affiliations & Notes
  • Shuai-Chun Lin
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Michael Waisbourd
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Sheryl S. Wizov
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Remy Serge Manzi Muhire
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Lisa A Hark
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • George L Spaeth
    Ophthalmology, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Shuai-Chun Lin, None; Michael Waisbourd, Merck Inc. (F); Sheryl Wizov, Merck Inc. (F); Remy Serge Manzi Muhire, Merck Inc. (F); Lisa Hark, Merck Inc. (F); George Spaeth, Merck Inc. (F), SPARCS (Patent No. 8,042,946) (P)
  • Footnotes
    Support  Merck Inc.; Glaucoma Service Foundation
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1973. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Shuai-Chun Lin, Michael Waisbourd, Sheryl S. Wizov, Remy Serge Manzi Muhire, Lisa A Hark, George L Spaeth; The impact of visual field progression on performance-based measures, vision-related quality of life, and clinical findings in patients with glaucoma: 2-year results. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1973.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the impact of visual field progression on measures of the ability to perform activities of daily leaving, vision-related quality of life (VRQoL), and clinical findings in patients with glaucoma.

Methods : Patients with moderate-stage glaucoma were studied. Subjects received an ocular examination, automated visual field (VF) test and spectral-domain optical coherence tomography scan. Contrast sensitivity was measured with the Pelli-Robson and the Spaeth-Richman Contrast Sensitivity Test (SPARCS). Vision-related performance was evaluated with the Compressed Assessment of Ability Related to Vision (CAARV). VRQoL and glaucoma symptoms were assessed by the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and the Modified Glaucoma Symptom Scale (MGSS). All tests were performed at baseline and at 1- and 2-year follow-up visits. Correlations between changes in VF mean deviation (MD) and the other outcome measures were computed. Comparisons of outcome measures were made between patients with and without VF progression (defined as MD change of ≥1dB/year loss).

Results : A total of 138 patients completed 2-year follow-up. The mean (SD) age was 65.6 (8.9) years. The mean rate of VF MD change over 2-year period was -0.27 dB/year. Significant correlations were found between VF change and: (1) contrast sensitivity measures (Pelli-Robson test: r=0.29, P=0.0006 and SPARCS total score: r=0.22, P=0.008); (2) VRQoL Measures (NEI-VFQ-25 subscales scores for mental health, role limitations, and driving: r=0.20, P=0.02; r=0.28, P=0.0009; r=0.20, P=0.03, respectively). Patients who had VF progression had significant change in their IOP, DDLS, and contrast sensitivity (Pelli-Robson and SPARCS total scores) compared with non-progressing patients (P<0.05). There was a trend toward significant difference in subscales of NEI-VFQ-25 between patients with VF progression and stable patients (P<0.10, Table 1).

Conclusions : VF progression in the better eye was positively correlated with contrast sensitivity measures and subjective measures of VRQoL after a 2-year period. Patients with VF progression had significantly decreased contrast sensitivity, increased IOP and DDLS, and a trend toward significant decrease in some NEI-VFQ-25 subscale scores compared with stable patients.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×